Semax Peptide: Complete Guide to Dosage, Benefits, and Protocols

Semax sits in an unusual position in the peptide landscape. It has genuine clinical approval in Russia, over 30 years of prescribing data, and a mechanism that most nootropic researchers find compelling. It is also one of the few neuropeptides where you can point to human trials rather than just animal data and anecdote.

It is not a relaxation peptide. Semax is activating. It raises brain-derived neurotrophic factor (BDNF), amplifies dopaminergic signaling, and is consistently reported to improve working memory, focus, and the kind of cognitive stamina that lets you stay locked in on complex work for longer. If you want calm, that is Selank. If you want drive and cognitive sharpness, that is Semax.

How Semax works

Semax is a synthetic analogue of the ACTH(4-7) fragment, the portion of adrenocorticotropic hormone that contains most of its nootropic activity but none of the hormonal effects of full ACTH. The "PGP" tail was added to extend its half-life and improve CNS penetration.

The primary mechanism is BDNF upregulation. BDNF (brain-derived neurotrophic factor) drives neuroplasticity, synaptogenesis, and the survival of existing neurons. Low BDNF correlates with depression, cognitive decline, and poor learning consolidation. Semax reliably raises BDNF levels within 20-30 minutes of intranasal administration in animal models, and the human clinical literature supports this effect at therapeutic doses.

Beyond BDNF, Semax modulates dopaminergic and serotonergic transmission, increases NGF (nerve growth factor) expression, and shows neuroprotective effects against oxidative stress. The combined effect is better described as optimizing the brain's operating conditions than as simple stimulation.

Cognitive and neuroprotective effects

The clinical literature on Semax is heavier than most peptides in this category because it has been studied in actual clinical settings in Russia since the early 1990s. A few consistent findings across the research:

• Working memory and attention: Improvement in attention-switching tasks and working memory capacity in healthy subjects and patients with cognitive impairment
• Stroke recovery: Approved in Russia for ischemic stroke as an adjunct therapy. Reduces neurological deficit scores in multiple trials
• ADHD-like focus: Commonly reported in research communities: reduced distractibility, better task persistence, less mental fatigue
• Mood lift: Not a primary effect, but many users report reduced mental fatigue and improved motivation as secondary effects of the BDNF elevation
• Neuroprotection: Reduces damage from hypoxia and ischemia in animal models; mechanism involves BDNF and NGF upregulation during stress

Important caveat: the Russian clinical trials are well-documented but use Russian regulatory standards, and most were conducted before the current evidence hierarchy became standard. The data is real, but treat it with the same critical eye you'd give any non-Western clinical literature.

Dosage and administration protocols

Intranasal dosing (most common route)

Intranasal Semax uses the olfactory pathway to bypass the blood-brain barrier. A solution administered via nasal spray reaches the CNS directly, which is why intranasal doses are lower than injection doses and onset is fast (20-40 minutes).

Concentration note: Semax for intranasal use is typically prepared at 0.1% (1 mg/ml) or 1% (10 mg/ml). A standard nasal spray pump delivers 50-100 mcl per spray. Know your concentration and spray volume before dosing.

Subcutaneous injection

Semax can be reconstituted for subQ injection, typically at 200-400 mcg per injection. The bioavailability via injection is higher than intranasal, so doses are often lower. Some researchers prefer injection for more precise dosing control. Onset is slightly slower (30-60 minutes) compared to intranasal.

Cycling

The standard protocol is 2-4 weeks on, followed by 1-2 weeks off. This preserves receptor sensitivity and prevents the tolerance development that some report with daily long-term use. The BDNF-elevating effects appear cumulative over a cycle, so the cognitive benefit tends to compound across the first 2-3 weeks before plateauing.

Semax vs Selank: how to choose

These two peptides are not competing for the same use case. Many researchers use both: Semax in the morning for focused productive work, Selank in the afternoon or evening when anxiety is the limiting factor rather than drive. They stack well together with no known adverse interaction.

If you can only pick one: Semax for someone whose problem is motivation and focus; Selank for someone whose problem is anxiety and rumination.

Side effects and safety

Semax has a relatively clean safety profile based on the Russian clinical literature and decades of prescribed use:

• Nasal irritation: Most common with intranasal use. Usually minor and fades with regular use. A well-prepared solution at appropriate concentration reduces this.
• Insomnia: The most common dose-dependent issue. Dose too late in the day and sleep quality drops. Keep all dosing before 2pm. If insomnia persists, drop to a morning-only protocol.
• Mild irritability or overstimulation: Occasionally reported at 900+ mcg. Reduce dose if this occurs.
• Headache: Occasionally reported, more common in the first few days of a cycle. Usually resolves.
• Appetite suppression: Minor and inconsistent, but noted by some users at higher doses.

No serious adverse events have been reported at research doses in the published clinical literature. Semax is not a controlled substance in the US, EU, or most Western jurisdictions, and does not appear on WADA's prohibited list.

What to expect across a cycle

Days 1-3: The most commonly noted acute effect is improved mental clarity and reduced cognitive fatigue within the first hour of dosing. Some users notice nothing on day 1 and respond more strongly by day 3.

Week 1-2: Working memory improvements become more apparent. Tasks that normally require mental effort feel less effortful. Sleep needs to be protected by maintaining morning-only dosing.

Week 2-4: The BDNF elevation appears to compound. Users in this window often report improved verbal recall, faster problem-solving, and a subjective sense of sharper thinking. Some report a rebound in mental energy after the cycle ends, consistent with the neuroplasticity effects settling in.

Off cycle: Most report no withdrawal or dependency. Some report a subtle drop in cognitive sharpness the first week off, which normalizes by week 2. The off period preserves receptor sensitivity for the next cycle.

Sourcing and quality considerations

Semax is relatively uncommon compared to BPC-157 or GHK-Cu, which means quality varies more across vendors. The intranasal preparation needs to be properly buffered for nasal pH and preserved against contamination. Key things to verify:

• COA confirming peptide identity and purity (98%+ target)
• Sterile preparation for nasal or injection use
• Proper cold-chain shipping (Semax in solution degrades faster than freeze-dried powder)
• Lot number matching the COA

The peptide bureau vendor scorecard includes vendors that carry Semax with verified COA documentation.

Stacking Semax

Semax + Selank: The most common nootropic stack. Semax in the morning, Selank afternoon or as needed for anxiety management. Complementary mechanisms with no known interaction risk.

Semax + GHK-Cu: Neuroprotective stack. GHK-Cu has its own BDNF-upregulating and gene expression effects. Used by researchers focused on long-term brain health and neuroplasticity rather than acute cognitive performance.

Semax + Dihexa: A more aggressive cognitive enhancement stack. Dihexa works on the HGF/c-Met pathway to promote synaptogenesis independently of the BDNF axis. The two mechanisms do not overlap, so stacking adds coverage. See the Dihexa guide for protocol details.